Search: onr:"swepub:oai:DiVA.org:liu-109695" > Apoptins :
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03301naa a2200421 4500 | |
001 | oai:DiVA.org:liu-109695 | |
003 | SwePub | |
008 | 140825s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1096952 URI |
024 | 7 | a https://doi.org/10.1016/j.molmed.2014.07.0032 DOI |
040 | a (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Rollano Penaloza, Oscar M.u Linköpings universitet,Avdelningen för cellbiologi,Hälsouniversitetet,Instituto de Biologia Molecular y Biotecnologia, La Paz, Bolivia4 aut |
245 | 1 0 | a Apoptins :b selective anticancer agents |
264 | 1 | b Elsevier BV,c 2014 |
338 | a print2 rdacarrier | |
520 | a Therapies that selectively target cancer cells for deathhave been the center of intense research recently. Onepotential therapy may involve apoptin proteins, whichare able to induce apoptosis in cancer cells leavingnormal cells unharmed. Apoptin was originally discoveredin the Chicken anemia virus (CAV); however, humangyroviruses (HGyV) have recently been found that alsoharbor apoptin-like proteins. Although the cancer cellspecific activity of these apoptins appears to be wellconserved, the precise functions and mechanisms ofaction are yet to be fully elucidated. Strategies for bothdelivering apoptin to treat tumors and disseminating theprotein inside the tumor body are now being developed,and have shown promise in preclinical animal studies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Cell- och molekylärbiologi0 (SwePub)301082 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Cell and Molecular Biology0 (SwePub)301082 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a anticancer agents; anaphase-promoting complex; CDK2; protein kinase C; protein phosphatase 2A. | |
700 | 1 | a Lewandowska, Magdalenau Pomeranian Medical University, Szczecin, Poland4 aut |
700 | 1 | a Stetefeld, Joergu University of Manitoba, Winnipeg, Canada4 aut |
700 | 1 | a Ossysek, Karolinau Jagiellonian University, Krakow, Poland4 aut |
700 | 1 | a Madej, Mariuszu Jagiellonian University, Krakow, Poland4 aut |
700 | 1 | a Bereta, Joannau Jagiellonian University, Krakow, Poland4 aut |
700 | 1 | a Sobczak, Mateuszu Jagiellonian University, Krakow, Poland4 aut |
700 | 1 | a Shojaei, Shahlau Shiraz University of Medical Sciences, Iran4 aut |
700 | 1 | a Ghavami, Saeidu University of Manitoba, Winnipeg, Canada and Shiraz University of Medical Sciences, Iran4 aut |
700 | 1 | a Los, Marek Janu Linköpings universitet,Avdelningen för cellbiologi,Hälsouniversitetet,Pomeranian Medical University, Szczecin, Poland4 aut0 (Swepub:liu)marlo14 |
710 | 2 | a Linköpings universitetb Avdelningen för cellbiologi4 org |
773 | 0 | t Trends in Molecular Medicined : Elsevier BVg 20:9, s. 519-528q 20:9<519-528x 1471-4914x 1471-499X |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-109695 |
856 | 4 8 | u https://doi.org/10.1016/j.molmed.2014.07.003 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.